Efficacy and Safety of Modern Biologics Compared to Conventional Therapies in AQP-4 Positive Neuromyelitis Optica Spectrum Disorder: A Fully AI-Automated Targeted Literature Review
Author(s)
Akansha Goel, M.S (Pharm.)1, Balpreet Singh, M.Sc Biochemistry2, Husna Tasneem Shaik, Masters in Health economics1, Anoop Aggarwal, PhD Pharmacology and Toxicology1, Amit Kishore, PhD1, Ahsaas Chawla, BE Chemical Engineering2, Rajinder Chawla, Phd Biochemistry1.
1HEOR, AccuScript Consultancy Pvt. Ltd, Ludhiana, India, 2AI Research and Development, AccuScript Consultancy Pvt. Ltd, Ludhiana, India.
1HEOR, AccuScript Consultancy Pvt. Ltd, Ludhiana, India, 2AI Research and Development, AccuScript Consultancy Pvt. Ltd, Ludhiana, India.
OBJECTIVES: To perform a fully automated targeted literature review (TLR) using artificial intelligence (AI) to compare the effectiveness of modern biologics with conventional therapies in patients with Aquaporin-4 positive Neuromyelitis Optica Spectrum Disorder (NMOSD).
METHODS: An in-house AI toolkit (SYMPRO-AI) was used to conduct an end-to-end fully automated targeted literature review (TLR). Based on the study objectives and protocol, the AI toolkit developed and executed a comprehensive PubMed search strategy. The full-text review (FTR) was also performed by SYMPRO-AI followed by a generative analysis on data from the identified studies. A complete TLR report comparing the two groups of treatment regimens was then automatically compiled. The TLR was completed within two hours from the searches to the report.
RESULTS: The AI-performed PubMed searches identified 1,721 citations, which were captured and saved by the toolkit. The SYMPRO-AI identified 130 articles on Title/Abstract screening that further reduced to 33 references by the automated FTR. The comparative analysis was then performed by AI toolkit that demonstrated the superior efficacy of modern biologics over conventional therapies, accelerating the process of evidence synthesis. Eculizumab, satralizumab, and inebilizumab showed significantly reduced annualized relapse rates (84-98%) compared to rituximab (74-100%) and traditional immunosuppressants (33-96%). Safety analysis also favored modern biologics, with lowest treatment discontinuation rates compared to conventional therapies.
CONCLUSIONS: Modern biologics show significantly better safety profile and superior efficacy in preventing relapses in adult AQP4-positive NMOSD patients compared to conventional therapies. The AI-based automated literature review by our in-house toolkit demonstrates the power of AI in performing complete reviews within 2-3 hours compared to a few weeks by manual processes. The AI pathways and efficacy comparison with manual processes will be presented.
METHODS: An in-house AI toolkit (SYMPRO-AI) was used to conduct an end-to-end fully automated targeted literature review (TLR). Based on the study objectives and protocol, the AI toolkit developed and executed a comprehensive PubMed search strategy. The full-text review (FTR) was also performed by SYMPRO-AI followed by a generative analysis on data from the identified studies. A complete TLR report comparing the two groups of treatment regimens was then automatically compiled. The TLR was completed within two hours from the searches to the report.
RESULTS: The AI-performed PubMed searches identified 1,721 citations, which were captured and saved by the toolkit. The SYMPRO-AI identified 130 articles on Title/Abstract screening that further reduced to 33 references by the automated FTR. The comparative analysis was then performed by AI toolkit that demonstrated the superior efficacy of modern biologics over conventional therapies, accelerating the process of evidence synthesis. Eculizumab, satralizumab, and inebilizumab showed significantly reduced annualized relapse rates (84-98%) compared to rituximab (74-100%) and traditional immunosuppressants (33-96%). Safety analysis also favored modern biologics, with lowest treatment discontinuation rates compared to conventional therapies.
CONCLUSIONS: Modern biologics show significantly better safety profile and superior efficacy in preventing relapses in adult AQP4-positive NMOSD patients compared to conventional therapies. The AI-based automated literature review by our in-house toolkit demonstrates the power of AI in performing complete reviews within 2-3 hours compared to a few weeks by manual processes. The AI pathways and efficacy comparison with manual processes will be presented.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
MSR82
Topic
Clinical Outcomes, Methodological & Statistical Research, Study Approaches
Topic Subcategory
Artificial Intelligence, Machine Learning, Predictive Analytics
Disease
Biologics & Biosimilars, Neurological Disorders, Rare & Orphan Diseases, Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)